[A short-term effect of lovastatin on lipoprotein metabolism in patients with cerebrovascular lesions concomitant with diabetes mellitus II type].
Changes of lipoprotein (LP) metabolism after lovastatin therapy (20 mg/day for 2 months) have been studied in patients with cerebrovascular lesions (CBL) concomitant with diabetes mellitus type 2 (DM-2) and in CBL patients without DM-2. Initial effect of lovastatin appeared in decreasing chilomicrone content in both groups of patients. A distinct trend towards restoration of processes converting apoA-containing LP being accompanied by normalization of function of the peripheral lipoprotein lipase bound form was observed. The data obtained support an opinion about rationality of lovastatin treatment of dyslipidemias in CBL concomitant with DM-2 as well as of cardiovascular pathology.
Bozhko
G Kh
GKh
Sokolik
V V
VV
Chursina
V S
VS
Pertseva
T G
TG
D015415:Biomarkers / Q000097:blood; D002561:Cerebrovascular Disorders / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood* / Q000187:drug effects; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D008148:Lovastatin